The shadow of generic challenges has consistently loomed around copyright’s iconic drug, Sildenafil, raising questions about the outlook of similar pharmaceutical investments. While first times saw substantial returns, the exclusivity end has allowed the way for less expensive alternatives, potentially diminishing earnings and presenting a signif